Haima Therapeutics Receives Phase I SBIR Contract from Department of Defense US Army to Develop its SynthoPlateTM Product

Cleveland, OH. September 5, 2018. Haima Therapeutics has been awarded a $150K Phase I SBIR contract from the US Army Research, Development, and Engineering Command (RDECOM) for research titled “Logistical and Functional Evaluation of SynthoPlateTM (Intravenous Synthetic Platelet) Technology for Pre-Hospital Hemorrhage Control”.

 

The funding will support studies on the lyophilization, shelf-life testing under extreme environmental conditions, and in vitro dosing optimization of SynthoPlateTM, a platelet-inspired synthetic hemostatic nanotechnology for intravenous mitigation of traumatic hemorrhage. These studies build on the currently active Phase I SBIR award of $225K from the National Science Foundation that Haima received to study batch-to-batch quality control in manufacturing of SynthoPlateTM as well as determining its shelf-life. These two back-to-back awards has led to Haima receiving a total of $375K in non-dilutive funding support this year for translational advancement of its SynthoPlateTM product.

 

Traumatic non-compressible hemorrhage remains one of the leading causes of mortality for the wounded military personnel in the battlefield. Although blood component transfusion is the best option to mitigate such hemorrhage, such blood products are majorly unavailable in the field. A product like SynthoPlateTM potentially addresses this need by providing a ‘synthetic platelet surrogate’ that can be administered at point-of-injury to stabilize and save wounded personnel.     

“We are very excited to receive funding support from the DoD to advance SynthoPlateTM as a potential lifesaver in pre-hospital trauma. These studies are critical to demonstrate the potential ability of bringing our hemostatic technology to the far forward battlefield environment for point-of-injury applications” said Dr. Michael Bruckman, Principle Investigator and Director of Technical Operations at Haima. SynthoPlateTM was invented in the laboratory of Dr. Anirban Sen Gupta in the Department of Biomedical Engineering at Case Western Reserve University and Haima Therapeutics was founded by Drs. Christa Pawlowski and Sen Gupta in 2016.   

 

In March 2018, Case Western Reserve University and Haima Therapeutics entered into an exclusive option agreement to license the SynthoPlateTM technology. 

 

About Haima Therapeutics:

Haima Therapeutics is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. We have developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlateTM, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. Learn more at www.haimatherapeutics.com and follow us on twitter @HaimaThr. For more information, please contact:

Michael Bruckman, PhD, Director of Technical Operations

mbruckman@haimatherapeutics.com